Secukinumab

Active substance
Secukinumab
Domain
Chronic immune diseases
Reason of inclusion in Horizonscan Geneesmiddelen
Indication extension
Main indication
Skin diseases
Extended indication
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

1. Product

Proprietary name
Cosentyx
Manufacturer
Novartis
Mechanism of action
Interleukin inhibitor
Route of administration
Subcutaneous
Therapeutical formulation
Injection
Budgetting framework
Intermural (MSZ)
Additional comments
Monklonaal antilichaam gericht tegen IL-17A.

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Submission date
November 2019
Expected Registration
August 2020
Orphan drug
No
Registration phase
Registration application pending
Additional comments
Fabrikant verwacht registratie in Q3 2020

3. Therapeutic value

Current treatment options
de volgende behandelingen zijn geregistreerd voor de behandeling van psoriasis, niet geselecteerd op leeftijd: adalimumab, golimumab, brodalumab, ixekizumab, secukinumab, infliximab, certolizumab pegol, etanercept, tofacitinib, baricitinib, ustekinumab, guselkumab, tildrakizumab, risankizumab, apremilast, abatacept.
Therapeutic value
Potential equal value
Substantiation
Er wordt verwacht dat secukinumab de concurrentie aan zal gaan met de andere anti-IL17 remmers.
Duration of treatment
Not found
References
NCT03668613

4. Expected patient volume per year

Patient volume

< 100

Market share is generally not included unless otherwise stated.

References
NHG-Standaard Psoriasis
Additional comments
Bij jonge kinderen is de prevalentie laag (ongeveer 0,4 per 1.000 patiƫnten per jaar). In Nederland zijn er 1,5 miljoen kinderen in de leeftijd van 6 tot 12 jaar. Dit betekent naar schatting 600 kinderen met deze indicatie. Naar verwachting gebruiken rond de 100 kinderen op dit moment biologicals deze groep komt mogelijk in aanmerking voor secukinumab.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.